Toll Free: 1-888-928-9744

Leiomyosarcoma - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 58 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Leiomyosarcoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Leiomyosarcoma - Pipeline Review, H2 2014', provides an overview of the Leiomyosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leiomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leiomyosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Leiomyosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Leiomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Leiomyosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Leiomyosarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Leiomyosarcoma - Overview 7
Pipeline Products for Leiomyosarcoma - Comparative Analysis 8
Leiomyosarcoma - Therapeutics under Development by Companies 9
Leiomyosarcoma - Therapeutics under Investigation by Universities/Institutes 10
Leiomyosarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Leiomyosarcoma - Products under Development by Companies 13
Leiomyosarcoma - Products under Investigation by Universities/Institutes 14
Leiomyosarcoma - Companies Involved in Therapeutics Development 15
GlaxoSmithKline plc 15
Novartis AG 16
Karyopharm Therapeutics, Inc. 17
Leiomyosarcoma - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
everolimus - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
pazopanib hydrochloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cell Therapy 3 for Oncology - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
selinexor - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Cell Therapy for Oncology and Infectious Diseases - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NOV-110501 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Leiomyosarcoma - Recent Pipeline Updates 43
Leiomyosarcoma - Dormant Projects 55
Leiomyosarcoma - Discontinued Products 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58
List of Tables
Number of Products under Development for Leiomyosarcoma, H2 2014 7
Number of Products under Development for Leiomyosarcoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Leiomyosarcoma - Pipeline by GlaxoSmithKline plc, H2 2014 15
Leiomyosarcoma - Pipeline by Novartis AG, H2 2014 16
Leiomyosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Leiomyosarcoma Therapeutics - Recent Pipeline Updates, H2 2014 43
Leiomyosarcoma - Dormant Projects, H2 2014 55
Leiomyosarcoma - Discontinued Products, H2 2014 56 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify